"Eye-Black" Sign Secondary to Nivolumab Immunotherapy. (March 2020)

• Record Type: Journal Article
• Authors: Priya, Sarv; Graham, Michael
• Is Part Of: Clinical nuclear medicine. Volume 45:Number 3(2020)
• Publication Date: 2020-03
• Subjects: eye-black -- FDG PET/CT -- immunotherapy adverse effect -- inflammatory -- nivolumab -- skin reaction; Nuclear medicine -- Periodicals; Radioisotope scanning -- Periodicals; Nuclear Medicine -- Periodicals; 616.07575
• DOI: 10.1097/RLU.0000000000002846
• Languages: English
• ISSNs: 0363-9762

Abstract

Abstract : Abstract: A 54-year-old woman with known chest wall melanoma (post–wide local excision) presented for imaging after a yearlong therapy with nivolumab. 18 F-FDG PET/CT was performed 1 day after she completed the immunotherapy. Maximum intensity projection images showed bilateral relatively symmetrical uptake in the facial region. On fused PET/CT images, the uptake was seen corresponding to subcutaneous malar prominence underneath the orbits (like eye-black stripe used in sports) with subcutaneous malar calcification. Repeat PET/CT performed after 3 months revealed significant decrease in the malar uptake. Interval resolution of the uptake likely suggested this being inflammatory and secondary to immunotherapy.